TITLE

Salix Liver-Failure Win Puts Spotlight on Xifaxan in IBS

AUTHOR(S)
Osborne, Randy
PUB. DATE
April 2010
SOURCE
BioWorld Today;4/5/2010, Vol. 21 Issue 64, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of Salix Pharmaceuticals' antibiotic Xifaxan for irritable bowel syndrome (IBS). The studies TARGET 1 and TARGET 2 have met primary and secondary endpoints in IBS. There are three forms of IBS, namely, diarrhea-predominant, constipation-predominant and mixed, in which the symptoms alternate. Salix's antibiotic is targeting diarrhea-predominant and mixed disease.
ACCESSION #
49013243

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics